Facial Angioedema after the first dose of Covishield (adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccine): follow-up after the second and third booster doses.
Rev Soc Bras Med Trop
; 55: e00632022, 2022.
Article
in English
| MEDLINE | ID: covidwho-1865364
ABSTRACT
Mass vaccination campaigns are essential to control the ongoing novel severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) pandemic. The Covishield vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, which contains the full-length structural spike protein of SARS-CoV-2. Occasionally, it can lead to cutaneous reactions that contribute to fear of vaccination, hesitancy, and incomplete vaccination schedules. We report a case of facial angioedema following the first dose of Covishield in a 63-year-old woman with no previous history of allergies or hypersensitivity to drugs or vaccines. No rebound of angioedema was recorded after the second homologous and third heterologous doses.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
ChAdOx1 nCoV-19
/
Angioedema
Type of study:
Case report
/
Cohort study
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Female
/
Humans
/
Middle aged
Language:
English
Journal:
Rev Soc Bras Med Trop
Year:
2022
Document Type:
Article
Affiliation country:
0037-8682-0063-2022
Similar
MEDLINE
...
LILACS
LIS